2. Academic Validation
  3. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

  • Neoplasia. 2018 May;20(5):478-488. doi: 10.1016/j.neo.2018.03.003.
Juan Jin 1,  Hehui Fang 1,  Fang Yang 1,  Wenfei Ji 2,  Nan Guan 3,  Zijia Sun 1,  Yaqin Shi 1,  Guohua Zhou 4,  Xiaoxiang Guan 5
Affiliations

Affiliations

  • 1 Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • 2 Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing Medical University, Nanjing, China.
  • 3 International Department American Division, Nanjing Jinling High School, Nanjing, China.
  • 4 Department of Pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • 5 Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China; Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing Medical University, Nanjing, China. Electronic address: xguan@nju.edu.cn.
PMID: 29605721 DOI: 10.1016/j.neo.2018.03.003
Abstract

Triple negative breast Cancer (TNBC) is a highly aggressive subtype of breast Cancer that poses a clinical challenge. Thus, new therapy strategies are urgently needed. The selective Wee1 Inhibitor, AZD1775, has shown strong anti-proliferative effects on a variety of tumors. Here, we first demonstrate that inhibition of ATR by selective inhibitor AZD6738 can enhance AZD1775-caused growth inhibition in TNBC. Our results show that the enhanced cell death is attributed to repressed DNA damage repair and excessive replication stress, thereby causing increased DNA damage reflected by accumulation of the DNA double-strand-break marker γH2AX. On the Other hand, combined treatment with AZD6738 and AZD1775 forces mitotic entry of cells with DNA damages by activating CDK1 activity, inducing severely aberrant mitosis and mitotic catastrophe, ultimately resulting in cell death. Dual inhibition of Wee1 and ATR also inactivated RAD51-mediated homologous recombination, which sensitized TNBC cells to cisplatin and PARP Inhibitor. Here, based on the preclinical results that ATR inhibition synergizes with Wee1 inhibition in TNBC, we propose that this combination therapy alone, or in parallel with chemotherapy, represents an innovative and potent targeted therapy in TNBC.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z